Additional Lyo bead automation ramps up manufacturing capacity

Biofortuna Limited (Deeside, UK), the specialist contract development and manufacturing partner to the IVD and point of care testing sectors, has invested in an additional Lyo bead manufacturing line in response to increasing customer demand for lyophilized diagnostic tests.

The new, fully automated platform has been configured to deliver custom lyophilized reagent beads at commercial scale, for use in a wide range of innovative molecular biology applications, including RT-PCR, LAMP and CRISPR.

Dr Nick Ash, CEO of Biofortuna said: “With an impressive pipeline of diagnostic tests under development for our customers, this increased capacity is essential.  Our infrastructure and knowhow is creating a positive impact on healthcare by improving the accuracy, speed and cost-effectiveness of cold-chain-free reagents, that also support our environmental and sustainability goals.

About Biofortuna

Biofortuna is a specialist laboratory services and diagnostic contract development and manufacturing organisation.  We provide genomic services, custom assay development and contract manufacturing solutions to empower our global partners in healthcare, biotechnology and academia to advance innovative life sciences and diagnostic applications in health and wellbeing.

The Company is ISO13485 and ISO17025 accredited, FDA registered, accredited by UK Government for DNA relationship testing and licensed by the Home Office for the storage of controlled drugs.

The Global Lyophilized Reagent Beads market was valued at USD188 million in 2023 and is anticipated to reach USD380 million by 2030, witnessing a CAGR of 11.0% during the forecast period 2024-2030. Valuates Reports 07 Sep 2024.